KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2025)

Pacific Biosciences Of California has reported Convertible Debt over the past 5 years, most recently at $645.4 million for Q4 2025.

  • Quarterly results put Convertible Debt at $645.4 million for Q4 2025, changed 0.33% from a year ago — trailing twelve months through Dec 2025 was $645.4 million (changed 0.33% YoY), and the annual figure for FY2025 was $645.4 million, changed 0.33%.
  • Convertible Debt for Q4 2025 was $645.4 million at Pacific Biosciences Of California, roughly flat from $645.2 million in the prior quarter.
  • Over the last five years, Convertible Debt for PACB hit a ceiling of $896.8 million in Q1 2023 and a floor of $645.2 million in Q3 2025.
  • Median Convertible Debt over the past 5 years was $892.8 million (2024), compared with a mean of $829.2 million.
  • Biggest five-year swings in Convertible Debt: increased 0.13% in 2024 and later fell 27.77% in 2025.
  • Pacific Biosciences Of California's Convertible Debt stood at $896.1 million in 2021, then increased by 0.07% to $896.7 million in 2022, then dropped by 0.5% to $892.2 million in 2023, then dropped by 27.43% to $647.5 million in 2024, then decreased by 0.33% to $645.4 million in 2025.
  • The last three reported values for Convertible Debt were $645.4 million (Q4 2025), $645.2 million (Q3 2025), and $646.4 million (Q2 2025) per Business Quant data.